Lessons from randomized phase III studies with active cancer immunotherapies - Outcomes from the 2006 Meeting of the Cancer Vaccine Consortium (CVC)

Vaccine

Volumn 25, Issue SUPPL. 2, 2007, Pages

  Finke, Lothar H ^a,g   Wentworth, Kerry ^b,g   Blumenstein, Brent ^c   Rudolph, Natalie S ^d   Levitsky, Hyam ^e,g   Hoos, Axel ^f,g  

^a Argos Therapeutics Inc   (United States)

^b Antigenics Inc   (United States)

^c TriArc Consulting   (United States)

^d Rudolph Biomedical Consulting   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g Cancer Vaccine Consortium (CVC)   (United States)

Author keywords

Active cancer immunotherapy; Development paradigm; Lessons; Phase III clinical studies

Indexed keywords

B7 ANTIGEN; BCG VACCINE; BISPHOSPHONIC ACID DERIVATIVE; CANCER VACCINE; CANVAXIN; CYCLOPHOSPHAMIDE; ENHANZYN; FAVID; GONADORELIN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR VACCINE; HEAT SHOCK PROTEIN; HEAT SHOCK PROTEIN 96; HLA ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; MELACINE; MONOCLONAL ANTIBODY BEC2; MYVAX; ONCOPHAGE; PHOSPHORYL LIPID A; PLACEBO; PROVENGE; THERATOPE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ANTIBODY RESPONSE; ANTIGEN EXPRESSION; BIOLOGICAL ACTIVITY; BIOLOGICAL THERAPY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CASE STUDY; CLINICAL TRIAL; COLORECTAL CANCER; CYTOTOXIC T LYMPHOCYTE; DRUG APPROVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FOOD AND DRUG ADMINISTRATION; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LICENSING; LUNG SMALL CELL CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; TARGET CELL; TREATMENT OUTCOME; UNITED STATES;

CANCER VACCINES; CLINICAL TRIALS, PHASE III AS TOPIC; DRUG APPROVAL; HUMANS; IMMUNOTHERAPY, ACTIVE; NEOPLASMS; QUALITY CONTROL; RESEARCH DESIGN;

EID: 34748918373     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.06.067     Document Type: Review

References (58)

1. ® biologics license application. Dendreon press release dated 9 May 2007 [cited 15 May 2007; available from: www.dendreon.com].
2. Sixth meeting of the Cancer Vaccine Consortium; 2006 November 10-11; Washington, DC. Final program and speaker slides available from: http://www.sabin.org/programs/cvc/cvc_meetings.html; 2006.
3. Bringing therapeutic cancer vaccines and immunotherapies through development to licensure: 2007 February 8-9. Final program available at https://cms.palladianpartners.com/cms/1156354418/home.htm#; videocast available at http://videocast.nih.gov/. Bethesda, MD; 2007.
4. Vaishampayan U., Abrams J., Darrah D., Jones V., and Mitchell M.S. Active immunotherapy of metastatic melanoma with allogeneic melanoma lysates and interferon alpha. Clin Cancer Res 8 12 (2002) 3696-3701
5. Mitchell M.S., Kan-Mitchell J., Kempf R.A., Harel W., Shau H.Y., and Lind S. Active specific immunotherapy for melanoma: phase I trial of allogeneic lysates and a novel adjuvant. Cancer Res 48 20 (1988) 5883-5893
6. Mitchell M.S., Harel W., Kempf R.A., Hu E., Kan-Mitchell J., Boswell W.D., et al. Active-specific immunotherapy for melanoma. J Clin Oncol 8 5 (1990) 856-869
7. Sondak V.K., Liu P.Y., Tuthill R.J., Kempf R.A., Unger J.M., Sosman J.A., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology Group. J Clin Oncol 20 8 (2002) 2058-2066
8. Mitchell M.S., Harel W., and Groshen S. Association of HLA phenotype with response to active specific immunotherapy of melanoma. J Clin Oncol 10 7 (1992) 1158-1164
9. Sosman J.A., Unger J.M., Liu P.Y., Flaherty L.E., Park M.S., Kempf R.A., et al. Adjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: impact of HLA class I antigen expression on outcome. J Clin Oncol 20 8 (2002) 2067-2075
10. Sondak V., Sosman J., Unger J.M., Liu P.Y., Thompson J., Tuthill R., et al. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. J Clin Oncol 22 14S (2004) 7501
11. Sondak V.K., Sosman J., Unger J.M., Liu P.Y., Thompson J., Tuthill R., et al. Significant impact of HLA class I allele expression on outcome in melanoma patients treated with an allogeneic melanoma cell lysate vaccine. Final analysis of SWOG-9035. J Clin Oncol 22 (2004) 7501 (meeting abstracts)
12. Morton D.L., Hsueh E.C., Essner R., Foshag L.J., O'Day S.J., Bilchik A., et al. Prolonged survival of patients receiving active immunotherapy with Canvaxin therapeutic polyvalent vaccine after complete resection of melanoma metastatic to regional lymph nodes. Ann Surg 236 4 (2002) 438-448 discussion 48-9
13. Morton D.L., Foshag L.J., Hoon D.S., Nizze J.A., Famatiga E., Wanek L.A., et al. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine. Ann Surg 216 4 (1992) 463-482
14. Barth A., Hoon D.S., Foshag L.J., Nizze J.A., Famatiga E., Okun E., et al. Polyvalent melanoma cell vaccine induces delayed-type hypersensitivity and in vitro cellular immune response. Cancer Res 54 13 (1994) 3342-3345
15. Hsueh E.C., Gupta R.K., Qi K., and Morton D.L. Correlation of specific immune responses with survival in melanoma patients with distant metastases receiving polyvalent melanoma cell vaccine. J Clin Oncol 16 9 (1998) 2913-2920
16. Chung M.H., Gupta R.K., Hsueh E., Essner R., Ye W., Yee R., et al. Humoral immune response to a therapeutic polyvalent cancer vaccine after complete resection of thick primary melanoma and sentinel lymphadenectomy. J Clin Oncol 21 2 (2003) 313-319
17. Hoon D.S., Okamoto T., Wang H.J., Elashoff R., Nizze A.J., Foshag L.J., et al. Is the survival of melanoma patients receiving polyvalent melanoma cell vaccine linked to the human leukocyte antigen phenotype of patients?. J Clin Oncol 16 4 (1998) 1430-1437
18. ® in stage IV melanoma. Medical News Today, 9 April 2005 [cited 12 April 2007]. Available from: http://www.medicalnewstoday.com/medicalnews.php?newsid=22446.
19. CancerVax announces results of phase III clinical trials of Canvaxin™ in patients with stage III and stage IV melanoma. Market Wire, 24 March 2006 [cited 12 April 2007]. Available from: http://www.marketwire.com/mw/release_html_b1?release_id=114480.
20. Terando A.M., Faries M.B., and Morton D.L. Vaccine therapy for melanoma: current status and future directions. Vaccine 25 Suppl 2 (2007) B4-B16
21. Assikis V.J., Daliani D., Pagliaro L., Wood C., Perez C., Logothetis C., et al. Phase II study of an autologous tumor derived heat shock protein-peptide complex vaccine (HSPPC-96) for patients with metastatic renal cell carcinoma (mRCC). Proc Am Soc Clin Oncol 22 (2003) 386
22. Aalamian M., Fuchs E., Gupta R., and Levey D.L. Autologous renal cell cancer vaccines using heat shock protein-peptide complexes. Urol Oncol 24 5 (2006) 425-433
23. Parmiani G., Licia R., Filiberto B., Alessandro T., Michele M., Giovanna A., et al. Vaccination of metastatic melanoma patients with the autologous heat-shock protein peptide complex-96 (HSPPC-96; Oncophage) which contains melanoma peptides, results in a specific T-cell response and clinical response. Proc Am Soc Clin Oncol (2002) 21 [abstract 49]
24. Pilla L., Squarcina P., Coppa J., Mazzaferro V., Huber V., Pende D., et al. Natural killer and NK-Like T-cell activation in colorectal carcinoma patients treated with autologous tumor-derived heat shock protein 96. Cancer Res 65 9 (2005) 3942-3949
25. Antigenics reports phase III results for Oncophage in kidney cancer. Antigenics Press Release dated 24 March 2006 [cited 10 April 2007]. Available from: www.antigenics.com.
26. GP96 heat shock protein-peptide complex vaccine in treating patients with recurrent or progressive glioma. ClinicalTrials.gov identifier NCT00293423 2006 [cited 23 April 2007]. Available from: http://www.clinicaltrials.gov.
27. Holmberg L.A., Oparin D.V., Gooley T., and Sandmaier B.M. The role of cancer vaccines following autologous stem cell rescue in breast and ovarian cancer patients: experience with the STn-KLH vaccine (Theratope). Clin Breast Cancer 3 Suppl 4 (2003) S144-S151
28. MacLean G.D., Miles D.W., Rubens R.D., Reddish M.A., and Longenecker B.M. Enhancing the effect of THERATOPE STn-KLH cancer vaccine in patients with metastatic breast cancer by pretreatment with low-dose intravenous cyclophosphamide. J Immunother Emphasis Tumor Immunol 19 4 (1996) 309-316
29. Holmberg L.A., Oparin D.V., Gooley T., Lilleby K., Bensinger W., Reddish M.A., et al. Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccine. Bone Marrow Transpl 25 12 (2000) 1233-1241
30. Miles D., and Papazisis K. Rationale for the clinical development of STn-KLH (Theratope) and anti-MUC-1 vaccines in breast cancer. Clin Breast Cancer 3 Suppl 4 (2003) S134-S138
31. Mayordomo J., Tres A., Miles D., Finke L., and Jenkins H. Long-term follow-up of patients concomitantly treated with hormone therapy in a prospective controlled randomized multicenter clinical study comparing STn-KLH vaccine with KLH control in stage IV breast cancer following first-line chemotherapy. J Clin Oncol 22 14S (2004) 2603
32. Ibrahim N.K., Murray J., Parker J., Finke L., and Miles D. Humoral immune-response to naturally occurring STn in metastatic breast cancer patients (MBC pts) treated with STn-KLH vaccine. J Clin Oncol 22 14S (2004) 2547
33. Fuentes R, Allman R, Mason MD. Ganglioside expression in lung cancer cell lines. Lung Cancer 1997;18(1):21-33.
34. Chapman P.B., Williams L., Salibi N., Hwu W.J., Krown S.E., and Livingston P.O. A phase II trial comparing five dose levels of BEC2 anti-idiotypic monoclonal antibody vaccine that mimics GD3 ganglioside. Vaccine 22 21-22 (2004) 2904-2909
35. Grant S.C., Kris M.G., Houghton A.N., and Chapman P.B. Long survival of patients with small cell lung cancer after adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmette-Guerin. Clin Cancer Res 5 6 (1999) 1319-1323
36. Giaccone G., Debruyne C., Felip E., Chapman P.B., Grant S.C., Millward M., et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). J Clin Oncol 23 28 (2005) 6854-6864
37. Petrulio C.A., and Kaufman H.L. Development of the PANVAC-VF vaccine for pancreatic cancer. Expert Rev Vaccines 5 1 (2006) 9-19
38. Marshall J.L., Gulley J.L., Arlen P.M., Beetham P.K., Tsang K.Y., Slack R., et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol 23 4 (2005) 720-731
39. Schuetz T., Kaufman H.L., Marshall J.L., and Safran H. Extended survival in second-line pancreatic cancer after therapeutic vaccination. J Clin Oncol 23 16S (2005) [abstract 2576]
40. Therion Biologics Corporation receives FDA agreement to initiate phase III clinical trial with PANVAC-VF in advanced pancreatic cancer. Therion Press Release dated May 24 2004 [cited 13 April 2007]. Available from: http://www.therionbio.com.
41. Therion reports results of phase III PANVAC-VF trial. Therion Press Release, June 28, 2006 [cited 13 April 2007]. Available from: www.therionbio.com.
42. Small E.J., Fratesi P., Reese D.M., Strang G., Laus R., Peshwa M.V., et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J Clin Oncol 18 23 (2000) 3894-3903
43. Burch P.A., Croghan G.A., Gastineau D.A., Jones L.A., Kaur J.S., Kylstra J.W., et al. Immunotherapy (APC8015, Provenge) targeting prostatic acid phosphatase can induce durable remission of metastatic androgen-independent prostate cancer: a Phase 2 trial. Prostate 60 3 (2004) 197-204
44. Small E.J., Schellhammer P.F., Higano C.S., Redfern C.H., Nemunaitis J.J., Valone F.H., et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol 24 19 (2006) 3089-3094
45. Cellular, Tissue and Gene Therapies Advisory Committee sipuleucel-T briefing document (BLA STN 125197/0). Seattle, WA: Dendreon Corporation; March 29, 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/briefing/2007-4291B1_01.pdf.
46. ® for hormone refractory prostate cancer. Dendreon Press Released dated March 29, 2007 [cited 13 April 2007]. Available from: www.dendreon.com.
47. ® (sipuleucel-T) active cellular immunotherapy treatment of metastatic prostate cancer after failing hormone therapy; 2007 [cited 13 April 2007]. Available from: http://www.clinicaltrials.gov/ct/show/NCT00065442?order=1.
48. ® licensure Dendreon Press Release dated 31 May 2007 [cited 31 May 2007]. Available from: www.dendreon.com.
49. Favrille announces interim analysis of secondary endpoint from pivotal phase III clinical trial of FavId following Rituxan. Favrille Press Release dated 14 November 2006 [cited 20 April 2007]. Available from: http://www.favrille.com.
50. Hurvitz S., and Timmerman J. Recombinant, tumour-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphomas: a focus on FavId. Expert Opin Biol Ther 5 6 (2005) 841-852
51. ® personalized immunotherapy phase III trial after second interim analysis. Press Release dated 27 July 2006 [cited 10 April 2007]. Available from: www.genitope.com.
52. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 3 (2000) 205-216
53. Rayman P., Wesa A.K., Richmond A.L., Das T., Biswas K., Raval G., et al. Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 10 18 Pt 2 (2004) 6360S-6366S
54. Jarnicki A.G., Lysaght J., Todryk S., and Mills K.H. Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol 177 2 (2006) 896-904
55. Hoos A., Parmiani G., Hege K., Sznol M., Loibner H., Eggermont A., et al. A clinical development paradigm for cancer vaccines and related biologics. J Immunother 30 1 (2007) 1-15
56. Pisano G.P. Can science be a business? Lessons from biotech. Harv Bus Rev 84 10 (2006) 114-124 50
57. Bernstein N. Enhancing cancer vaccines with immunomodulators. Vaccine 25 Suppl 2 (2007) B72-B88
58. Gulley J.L., Madan R.A., and Arlen P.M. Enhancing efficacy of therapeutic vaccinations by combination with other modalities. Vaccine 25 Suppl 2 (2007) B89-B96